| Singapore’s Temasek Holdings along with other investors invested a round of US$ 89 million in Portola Pharmaceuticals via preferred equity. Portola Pharmaceuticals is a San Francisco biotech company that is working on an anti-clotting drug called betrixaban.
This financing is for pushing the development through its Phase III betrixaban trial. Eight months ago Merck dropped its collaborative efforts with Portola Pharmaceuticals. Temasek Holdings has been an active investor in venture capital investments in the Silicon Valley...............................................Full Article: Source
|